Expanded access Science 37 specializes in decentralized clinical trials delivering direct-to-patient site access, presenting a clear sales opportunity to grow partnerships with life sciences companies seeking faster enrollment and broader patient diversity.

Awarded credibility Recent industry recognition including Frost & Sullivan Global Company of the Year and the Site Innovation R&D award bolster credibility when engaging potential sponsors and can shorten decision cycles for new collaborations.

Core capability The Direct-to-Patient model and nationwide reach align with sponsor goals for faster trial timelines and improved retention, offering a compelling value proposition to biopharma and CROs looking to de-risk decentralized trial deployments.

Strategic partnerships Recent collaborations (for example with CGD Association of America) highlight potential for co-sponsored studies and access to specialized patient populations, suggesting growth opportunities with disease-specific advocacy groups and researchers.

Scale and tech A technology stack leveraging cloud, analytics, and customer support tools (AWS Fargate, New Relic, Zendesk, NetSuite) indicates the ability to scale operations and deliver measurable performance improvements for trial sponsors, a strong talking point for ROI-driven conversations.